U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended September 30, 2004

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                  to
                                    -----------------   ---------------

                       Commission File No. 000-49655
                                           ---------


                         LIPIDVIRO TECH, INC.
                         --------------------
     (Exact Name of Small Business Issuer as specified in its Charter)


            Nevada                                     87-0678927
            ------                                     ----------
  (State or Other Jurisdiction of                (I.R.S. Employer I.D. No.
incorporation or organization)


                        2120 South 700 East, #H183
                        Salt Lake City, Utah 84106
                        --------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (801) 583-9900
                                            --------------

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                                     N/A

     Check whether the Registrant filed all documents and reports required to
be filed by Section 12, 13, or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.  Yes    No

                   APPLICABLE ONLY TO CORPORATE ISSUERS

     State the number of shares outstanding of each of the Registrant's
classes of common equity, as of the latest practicable date:

                           September 30, 2004

              Common Voting Stock - 10,031,863 shares

Transitional Small Business Disclosure Format (Check one):  Yes X   No


ITEM 1 Financial Statements

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management and commence below,
together with related Notes.  In the opinion of management, the Financial
Statements fairly present the financial condition of the Registrant.
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

      UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

                        SEPTEMBER 30, 2004
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]




                             CONTENTS

                                                               PAGE

        Unaudited Condensed Consolidated Balance
             Sheets, September 30, 2004 and December 31,
             2003                                                   2


        Unaudited Condensed Consolidated Statements of
             Operations, for the three and nine months ended
             September 30, 2004 and from inception on May 6,
             2003 through September 30, 2003 and 2004               3


        Unaudited Condensed Consolidated Statements of
             Cash Flows, for the nine months ended
             September 30, 2004 and from inception on May 6,
             2003 through September 30, 2003 and 2004               4


        Notes to Unaudited Condensed Consolidated
             Financial Statements                              5 - 13
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

         UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

                              ASSETS
                                                 September 30,   December 31,
                                                      2004          2003
                                                   ___________   ___________
CURRENT ASSETS:
  Cash                                             $     5,094   $     3,702
  Prepaid expense                                            -         3,919
                                                   ___________   ___________
        Total Current Assets                             5,094         7,621
                                                   ___________   ___________

PROPERTY AND EQUIPMENT, net                              2,636         2,118
                                                   ___________   ___________

OTHER ASSETS:
  Definite-life intangible assets, net                  20,265             -
  Goodwill                                             290,317       269,006
                                                   ___________   ___________
        Total Other Assets                             310,582       269,006
                                                   ___________   ___________

                                                   $   318,312   $   278,745
                                                   ___________   ___________

               LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES:
  Accounts payable                                 $    37,373   $    26,387
  Shareholder advances                                 192,500        65,000
                                                   ___________   ___________
        Total Current Liabilities                      229,873        91,387
                                                   ___________   ___________

STOCKHOLDERS' EQUITY [Restated]:
  Common stock, $.001 par value,
   150,000,000 shares authorized,
   10,031,862 and 9,818,750 shares
   issued and outstanding, respectively                 10,032         9,819
  Capital in excess of par value                       344,352       323,254
  Deficit accumulated during the
   development stage                                  (265,945)     (145,715)
                                                   ___________   ___________
        Total Stockholders' Equity                      88,439       187,358
                                                   ___________   ___________

                                                   $   318,312   $   278,745
                                                   ___________   ___________

Note: The balance sheet at December 31, 2003 was taken from the audited
   financial statements at that date and condensed.

The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.

                               F-2
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS


                            For the Three    For the Nine  From Inception on
                            Months Ended     Months Ended  May 6, 2003 Through
                            September 30,    September 30,    September 30,
                          __________________ _____________ __________________
                           2004      2003        2004       2003       2004
                          ________  ________   _________   ________ _________
REVENUE                   $      -  $      -   $       -   $      - $       -
                          ________  ________   _________   ________ _________
EXPENSES:
  General and
   administrative           34,184    27,610      57,690     32,920   137,847
  Research and development  13,383     9,485      62,540     55,469   128,098
                          ________  ________   _________   ________ _________
      Total Expenses        47,567    37,095     120,230     88,389   265,945
                          ________  ________   _________   ________ _________

LOSS BEFORE INCOME
  TAXES                    (47,567)  (37,095)   (120,230)   (88,389) (265,945)

CURRENT TAX EXPENSE
  (BENEFIT)                      -         -           -          -         -

DEFERRED TAX EXPENSE
  (BENEFIT)                      -         -           -          -         -
                          ________  ________   _________   ________ _________

NET LOSS                  $(47,567) $(37,095)  $(120,230)  $(88,389)$(265,945)
                          ________  ________   _________   ________ _________

LOSS PER COMMON SHARE     $   (.00) $   (.00)  $    (.00)  $   (.01)$    (.02)
                          ________  ________   _________   ________ _________



The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.

                               F-3
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

    UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

                                                            From Inception on
                                          For the Nine     May 6, 2003 Through
                                          Months Ended         September 30,
                                          September 30,  _____________________
                                              2004           2003      2004
                                          __________     __________ __________
Cash Flows from Operating Activities:
 Net loss                                 $ (120,230)    $  (88,389)$(265,945)
 Adjustments to reconcile net loss to net
 cash used by operating activities:
  Depreciation expense                           602             87       787
  Non-cash expenses paid by issuance of
  common stock                                     -            750       750
  Non-cash services paid by issuance of
  common stock                                     -            113       113
  Changes in assets and liabilities:
   Decrease (increase) in prepaid expense      3,919          6,096         -
   Increase in accounts payable               10,986              -    37,373
   Increase in accrued expenses                    -              -         -
                                          __________     __________ _________
        Net Cash (Used) by Operating
        Activities                          (104,723)       (81,343) (226,922)
                                          __________     __________ _________
Cash Flows from Investing Activities:
 Payments for property and equipment            (960)        (1,870)   (3,263)
 Payments for definite-life intangible
  assets                                     (20,425)             -   (20,425)
 Payments for goodwill                             -       (269,006) (269,006)
                                          __________     __________ _________
        Net Cash (Used) by Investing
        Activities                           (21,385)      (270,876) (292,694)
                                          __________     __________ _________
Cash Flows from Financing Activities:
 Proceeds from bank overdrafts                     -              9         -
 Proceeds from shareholder advances          127,500         20,000   192,500
 Proceeds from issuance of common stock            -        293,700   293,700
 Proceeds from sale of warrants                    -         38,510    38,510
                                          __________     __________ _________
        Net Cash Provided by Financing
        Activities                           127,500        352,219   524,710
                                          __________     __________ _________
Net Increase (Decrease) in Cash                1,392              -     5,094

Cash at Beginning of Period                    3,702              -         -
                                          __________     __________ _________
Cash at End of Period                     $    5,094     $        - $   5,094
                                          __________     __________ _________
Supplemental Disclosures of Cash Flow Information:
 Cash paid during the period for:
   Interest                               $        -     $        - $       -
   Income taxes                           $        -     $        - $       -

Supplemental Schedule of Non-cash Investing and Financing Activities:
 For the period from inception on May 6, 2003 through June 30, 2004:
  In January 2004, the Company issued 213,112 shares of common stock as part
  of a downstream merger [See Note 2].

  In June 2003, the Company issued 3,750 shares of common stock for services
  rendered valued at $113.

  In May 2003, the Company issued 25,000 shares of common stock as repayment
  of organization costs of $750.


The accompanying notes are an integral part of these unaudited condensed
consolidated financial statements.

                               F-5
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

    Organization - LipidViro Tech, Inc. ("Parent") was organized under the
    laws of the State of California on October 19, 1954 as Anticline
    Uranium, Inc.  In October 2001, Parent changed its domicile from
    California to Nevada by merging with and into a wholly owned subsidiary
    with the same name and the Nevada entity being the surviving entity.  In
    January 2004, Parent changed its name to LipidViro Tech, Inc.  On June
    24, 2003, Subsidiary acquired 95.9% of the outstanding stock of Parent
    pursuant to a Share Purchase Agreement.  The agreement called for
    Subsidiary to pay $65,718 to the former shareholders of Parent for
    5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
    owned subsidiary of Subsidiary [See Note 3].  On January 14, 2004,
    Parent issued 9,818,750 shares of its common stock for all 9,818,750
    outstanding shares of Subsidiary's common stock wherein Subsidiary
    became a wholly owned subsidiary of Parent in a transaction which has
    been accounted for as a downstream merger [See Note 2].  Accordingly,
    the equity transactions have been restated to reflect the
    recapitalization of Subsidiary and the operations of Parent prior to
    June 24, 2003 have been eliminated.  The financial statements reflect
    the operations of Subsidiary from its inception.

    Lipidviro Tech Inc. ("Subsidiary") was organized under the laws of the
    State of Utah on May 6, 2003.

    LipidViro Tech, Inc. and Subsidiary ("the Company") plans to research
    and market substances and compounds for antiviral and antibacterial
    purposes.  The Company has not generated any revenues from their planned
    principal operations and is considered a development stage company as
    defined in Statement of Financial Accounting Standards No. 7.  The
    Company has, at the present time, not paid any dividends and any
    dividends that may be paid in the future will depend upon the financial
    requirements of the Company and other relevant factors.

    Condensed Financial Statements - The accompanying financial statements
    have been prepared by the Company without audit.  In the opinion of
    management, all adjustments (which include only normal recurring
    adjustments) necessary to present fairly the financial position, results
    of operations and cash flows at September 30, 2004 and for the periods
    then ended have been made.

    Certain information and footnote disclosures normally included in
    financial statements prepared in accordance with generally accepted
    accounting principles in the United States of America have been
    condensed or omitted.  It is suggested that these condensed financial
    statements be read in conjunction with the financial statements and
    notes thereto included in the Company's December 31, 2003 audited
    financial statements.  The results of operations for the periods ended
    September 30, 2004 are not necessarily indicative of the operating
    results for the full year.

    Consolidation - The consolidated financial statements include the
    accounts of Parent and Parent's wholly owned Subsidiary.  All
    significant intercompany transactions have been eliminated in
    consolidation.

    Cash and Cash Equivalents - The Company considers all highly liquid debt
    investments purchased with a maturity of three months or less to be cash
    equivalents.
                               F-5
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

    Property and Equipment - Property and equipment are stated at cost.
    Expenditures for major renewals and betterments that extend the useful
    lives of property and equipment are capitalized upon being placed in
    service.  Expenditures for maintenance and repairs are charged to
    expense as incurred.  Depreciation is computed using the straight-line
    method over the estimated useful lives of the assets of five years.  In
    accordance with Statement of Financial Accounting Standards No. 144,
    "Accounting for the Impairment or Disposal of Long-Lived Assets", the
    Company periodically reviews their property and equipment for
    impairment.

    Website Costs - The Company has adopted the provisions of Emerging
    Issues Task Force 00-2, "Accounting for Web Site Development Costs."
    Costs incurred in the planning stage of a website are expensed as
    research and development while costs incurred in the development stage
    are capitalized and amortized over the life of the asset, estimated to
    be five years.  As of September 30, 2004, the Company has capitalized a
    total of $2,830 of website costs which are included in property and
    equipment.  The Company did not incur any planning costs and did not
    record any research and development costs for the nine months ended
    September 30, 2004.

    Intangible Assets - The Company accounts for their intangible assets in
    accordance with Statement of Financial Accounting Standards No. 142,
    "Goodwill and Other Intangible Assets".  SFAS No. 142 establishes three
    classifications for intangible assets including definite-life intangible
    assets, indefinite-life intangible assets and goodwill and requires
    different accounting treatment and disclosures for each classification.
    In accordance with SFAS No. 142, the Company periodically reviews their
    intangible assets for impairment.  No impairment was recorded during the
    nine months ended September 30, 2004.

    Research and Development - Research and development costs are expensed
    as incurred.  The Company expensed $62,540 in research and development
    costs during the nine months ended September 30, 2004.

    Income Taxes - The Company accounts for income taxes in accordance with
    Statement of Financial Accounting Standards No. 109 "Accounting for
    Income Taxes" [See Note 8].

    Minority Interest - From June 24, 2003 through January 14, 2004,
    Subsidiary owned 95.9% of Parent.  The net loss of Parent applicable to
    the non-controlling minority interest was not allocated to the minority
    interests as there was no obligation of the non-controlling minority
    interests to share in such losses.  On January 14, 2004, Subsidiary
    acquired the minority interest in a downstream merger [See Note 2].

    Loss Per Share - The computation of loss per share is based on the
    weighted average number of shares outstanding during the period
    presented in accordance with Statement of Financial Accounting Standards
    No. 128, "Earnings Per Share" [See Note 11].
                               F-6
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Continued]

    Accounting Estimates - The preparation of financial statements in
    conformity with generally accepted accounting principles in the United
    States of America requires management to make estimates and assumptions
    that affect the reported amounts of assets and liabilities, the
    disclosures of contingent assets and liabilities at the date of the
    financial statements, and the reported amount of revenues and expenses
    during the reported period.  Actual results could differ from those
    estimated.

    Recently Enacted Accounting Standards - Statement of Financial
    Accounting Standards ("SFAS") No. 149, "Amendment of Statement 133 on
    Derivative Instruments and Hedging Activities", and SFAS No. 150,
    "Accounting for Certain Financial Instruments with Characteristics of
    both Liabilities and Equity", were recently issued.  SFAS No. 149 and
    150 have no current applicability to the Company or their effect on the
    financial statements would not have been significant.

    Reclassification - The financial statements for periods prior to
    September 30, 2004 have been reclassified to conform to the headings and
    classifications used in the September 30, 2004 financial statements.

    Restatement - The financial statements have been restated for all
    periods presented to reflect the recapitalization of Subsidiary [See
    Note 2] and to reflect a 1-for-100 reverse stock split that Parent
    effected on October 4, 2001 and a 4-for-1 forward stock split that
    Parent effected on December 31, 2001 [See Note 7].

NOTE 2 - DOWNSTREAM MERGER

    On January 14, 2004, Subsidiary acquired the minority interests in
    Parent and Subsidiary was reorganized as a subsidiary of Parent in a
    transaction in which Parent issued 9,818,750 shares of its common stock
    in exchange for all 9,818,750 outstanding shares of Subsidiary's common
    stock.  Accordingly, the equity transactions have been restated to
    reflect the recapitalization of Subsidiary.  The Company recorded
    goodwill of $21,311 as a result of the downstream merger.  The financial
    statements reflect the operations of Subsidiary from its inception.  As
    part of the downstream merger, Parent issued 1,915,000 Class A warrants
    and 1,915,000 Class B warrants to replace similar warrants of
    Subsidiary.  Parent also cancelled 5,000,000 shares of its common stock
    which had previously been owned by Subsidiary.

NOTE 3 - ACQUISITION OF 95.9% OF LIPIDVIRO TECH, INC.

    On June 24, 2003, Subsidiary acquired 95.9% of the outstanding stock of
    Parent pursuant to a Share Purchase Agreement.  The agreement called for
    Subsidiary to pay $65,718 to the former shareholders of Parent for
    5,000,000 shares of Parent's common stock wherein Parent became a 95.9%
    owned subsidiary of Subsidiary.  The agreement also called for
    Subsidiary to advance an additional $203,282 to pay costs associated
    with the acquisition and to reduce the liabilities of Parent.  The
    acquisition closed June 24, 2003 and has been accounted for as a
    purchase of Parent.  The Company recorded goodwill of $269,006 as a
    result of the acquisition.  The financial statements reflect the
    operations of Parent from June 24, 2003.

                               F-7
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 4 - PROPERTY AND EQUIPMENT

  Property and equipment consisted of the following at:

                                                  September 30,  December 31,
                                                       2004         2003
                                                   ___________   ___________
     Office equipment                              $       433   $       433
     Website                                             2,830         1,870
                                                   ___________   ___________
                                                         3,263         2,303

     Less: accumulated depreciation                      (627)          (185)
                                                   ___________   ___________
     Net property and equipment                    $     2,636   $     2,118
                                                   ___________   ___________

  Depreciation expense for the nine months ended September 30, 2004 was $442.

NOTE 5 - DEFINITE-LIFE INTANGIBLE ASSETS

     Definite-life intangible assets consist of the following at:

                                                  September 30,  December 31,
                                                       2004         2003
                                                   ___________   ___________
     Pending Patents                               $    19,809   $         -

     Patent applications in process                        616             -
                                                   ___________   ___________
                                                        20,425             -

     Less: Accumulated amortization                       (160)            -
                                                   ___________   ___________
     Net Definite-life Intangible Assets           $    20,265   $         -
                                                   ___________   ___________

  The Company's definite-life intangible assets are amortized, upon being
  placed in service, over the estimated useful lives of the assets of 20
  years with no residual value.  Amortization expense for the nine months
  ended September 30, 2004 and for the period from inception on May 6, 2003
  through September 30, 2003 was $160 and $0, respectively.  The Company
  estimates that their amortization expense for each of the next five years
  will be approximately $1,000 per year.

                               F-8
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 6 - GOODWILL

  The Company has no indefinite-life intangible assets.  The following is a
  summary of the transactions affecting the Company's goodwill.

                                                       From Inception on
                          For the Three  For the Nine  May 6, 2003 Through
                           Months Ended  Months Ended     September 30,
                          September 30,  September 30, ______________________
                               2004         2004           2003       2004
                           ___________  ______________ __________ ___________
Goodwill at beginning of
    period                 $   290,317  $      269,006 $        - $         -

Goodwill from the
    acquisition of 95.9% of
    Parent                           -               -    269,006     269,006

Goodwill from the
    acquisition of the
    minority interests in
    Parent                           -          21,311          -      21,311
                           ___________  ______________ __________ ___________

Goodwill at end of period  $   290,317  $      290,317 $  269,006 $   290,317
                           ___________  ______________ __________ ___________

NOTE 7 - CAPITAL STOCK

  Common Stock - The Company has authorized 150,000,000 shares of common
  stock with a par value of $.001.

  In January 2004, the Company issued 213,112 shares of their previously
  authorized but unissued common stock to the former shareholders of
  Subsidiary as part of a downstream merger [See Note 2].

  In June 2003, the Company issued 3,750 shares of their previously
  authorized but unissued common stock to an officer of the Company for
  services rendered valued at $113, or $.03 per share.

  In June 2003, the Company issued 7,875,000 shares of their previously
  authorized but unissued common stock for cash of $236,250, or .03 per
  share.

  In May 2003, the Company issued 1,915,000 units.  Each unit consisted of
  one share of the Company's previously authorized but unissued common stock,
  one Class A warrant and one Class B warrant.  The units were issued for
  cash of $95,960, or approximately $.05 per unit.

  In May 2003, in connection with their organization, the Company issued
  25,000 shares of their previously authorized but unissued common stock to
  an officer of the Company as repayment of organization costs of $750, or
  $.03 per share.
                               F-9
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 7 - CAPITAL STOCK [Continued]

  Stock Splits - On December 31, 2001, Parent effected a 4-for-1 forward
  stock split.  On October 4, 2001, Parent effected a 1-for-100 reverse stock
  split.  The financial statements for all periods presented have been
  restated to reflect these stock splits.

  Class A Warrants - In May 2003, the Company issued 1,915,000 Class A
  Warrants for cash of $19,255, or approximately $.01 per warrant, as part of
  a private placement offering.  The warrants vested immediately and are
  exercisable at $5.00 per share.  The warrants were originally exercisable
  for two years.  In August 2003, the Company changed the exercise period so
  the warrants are only exercisable during June 2006.  At September 30, 2004,
  none of these warrants had been exercised, forfeited or cancelled.

  Class B Warrants - In May 2003, the Company issued 1,915,000 Class B
  Warrants for cash of $19,255, or approximately $.01 per warrant, as part of
  a private placement offering.  The warrants vested immediately and are
  exercisable at $10.00 per share.  The warrants were originally exercisable
  for two years.  In August 2003, the Company changed the exercise period so
  the warrants are only exercisable during June 2006.  At September 30, 2004,
  none of these warrants had been exercised, forfeited or cancelled.

  Stock Option Plan - In March 2003, the Board of Directors of Parent
  approved and adopted the "2003 Stock Option/Stock Issuance Plan" ("the
  Plan") with a maximum of 1,500,000 shares of common stock reserved for
  issuance under the Plan.  The Plan provides for both the direct award of
  shares and for the grant of options to purchase shares.  The Board of
  Directors has authorized options to purchase 500,000 common shares to be
  granted at a purchase price of $0.01 per share, but to date the Company has
  not granted any options to their employees, officers or directors.  Under
  the Plan, the Board of Directors shall determine which eligible persons are
  to receive Incentive Options, Non-Statutory grants or stock issuances.  The
  Board of Directors also sets the exercise price for options granted.  The
  option terms are not to exceed ten years from the option grant date.  At
  September 30, 2004, total awards available to be granted from the Plan
  amounted to 1,500,000.

NOTE 8 - INCOME TAXES

  The Company accounts for income taxes in accordance with Statement of
  Financial Accounting Standards No. 109, "Accounting for Income Taxes".
  SFAS No. 109 requires the Company to provide a net deferred tax
  asset/liability equal to the expected future tax benefit/expense of
  temporary reporting differences between book and tax accounting methods and
  any available operating loss or tax credit carryforwards.  The Company has
  available at September 30, 2004 unused operating loss carryforwards of
  approximately $343,000 which may be applied against future taxable income
  and which expire in various years through 2024.  Due to substantial changes
  in the Company's ownership, there will be an annual limitation on the
  amount of net operating loss carryforwards which can be utilized.
                               F-10
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 8 - INCOME TAXES [Continued]

  The amount of and ultimate realization of the benefits from the operating
  loss carryforwards for income tax purposes is dependent, in part, upon the
  tax laws in effect, the future earnings of the Company, and other future
  events, the effects of which cannot be determined.  Because of the
  uncertainty surrounding the realization of the deferred tax assets, the
  Company has established a valuation allowance equal to the tax effect of
  the loss carryforwards, therefore, no deferred tax asset has been
  recognized.  The net deferred tax assets, which consist of difference in
  book and tax basis of fixed assets and net operating losses, are
  approximately $63,900 and $38,400 as of September 30, 2004 and December 31,
  2003, respectively, with an offsetting valuation allowance of the same
  amount, resulting in a change in the valuation allowance of approximately
  $25,500 during the nine months ended September 30, 2004.

NOTE 9 - RELATED PARTY TRANSACTIONS

  Management Compensation - The Company has not paid any cash compensation to
  any officer or director of the Company.  However, in June 2003, the Company
  issued 3,750 shares of common stock to an officer of the Company for
  services rendered valued at $113 [See Note 7].

  Office Space - The Company has not had a need to rent office space.  A
  shareholder (former officer) of the Company is allowing the Company to use
  her mailing address, as needed, at no expense to the Company.

  Stock Issuance - In May 2003, in connection with their organization, the
  Company issued 25,000 shares of their previously authorized but unissued
  common stock to an officer of the Company as repayment of organization
  costs of $750, or $.03 per share.

  Shareholder Advances - During the nine months ended September 30, 2004, a
  shareholder of the Company advanced $127,500 to the Company.  At September
  30, 2004, the Company owes a total of $192,500 to the shareholder.  The
  advances bear no interest and are due December 31, 2004.

NOTE 10 - GOING CONCERN

  The accompanying financial statements have been prepared in conformity with
  generally accepted accounting principles in the United States of America,
  which contemplate continuation of the Company as a going concern.  However,
  the Company was only recently formed and has not yet been successful in
  establishing profitable operations.  Further, the Company has current
  liabilities in excess of current assets.  These factors raise substantial
  doubt about the ability of the Company to continue as a going concern.  In
  this regard, management is proposing to raise any necessary additional
  funds not provided by operations through loans or through additional sales
  of their common stock.  There is no assurance that the Company will be
  successful in raising this additional capital or in achieving profitable
  operations.  The financial statements do not include any adjustments that
  might result from the outcome of these uncertainties.
                               F-11
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 11 - LOSS PER SHARE

  The following data shows the amounts used in computing loss per share:

                            For the Three     For the      From Inception on
                            Months Ended    Nine Months   May 6, 2003 Through
                            September 30,     Ended           September 30,
                         __________________ September    ____________________
                           2004      2003    30, 2004      2003       2004
                         ________  ________  ________    ________  __________
Loss from continuing
operations available to
common shareholders
(numerator)              $(47,567) $(37,095) $(120,230)  $(88,398) $ (265,945)
                         ________  ________  _________   ________  __________
Weighted average number
of common shares
outstanding used in loss
per share for the period
(denominator)          10,031,862  9,818,750  10,020,973  7,732,934  9,329,070
                       __________  _________  __________  _________  _________

  At June 30, 2004, the Company had 1,915,000 Class A warrants and 1,915,000
  Class B warrants outstanding which were not used in the computation of
  dilutive loss per share because their effect would be anti-dilutive.
  Dilutive loss per share was not presented, as the Company had no common
  stock equivalent shares for all periods presented that would effect the
  computation of diluted loss per share.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

  Agreements - In August 2004, the Company signed a one-year agreement for
  the use of a research facility and staff to conduct research on behalf of
  the Company and to have a researcher coordinate the activities.  The
  Company agreed to pay up to $600,000 for supplies, facilities, a laboratory
  technician and coordination efforts.  During the nine months ended
  September 30, 2004 and the period from inception on May 6, 2003 through
  September 30, 2003, respectively, the Company paid $5,000 and $0 under this
  agreement.  Through September 30, 2004, the Company has paid a total of
  $5,000 under this agreement.

  In July 2004, the Company signed a six-month agreement for a researcher to
  conduct research on behalf of the Company.  The Company agreed to pay
  $15,000 for the services of the researcher.  During the nine months ended
  September 30, 2004 and the period from inception on May 6, 2003 through
  September 30, 2003, respectively, the Company paid $5,000 and $0 under this
  agreement.  Through September 30, 2004, the Company has paid a total of
  $5,000 under this agreement.

  In October 2003, the Company signed one-year agreements for the use of a
  research facility and staff to conduct research on behalf of the Company
  and to have a researcher coordinate the activities.  The Company agreed to
  pay up to $76,325 for supplies, facilities, a laboratory technician and
  coordination efforts.  The costs incurred under this agreement totaled
  $75,000.  During the nine months ended September 30, 2004 and the period
  from inception on May 6, 2003 through September 30, 2003, respectively, the
  Company paid $52,000 and $0 under these agreements.  Through September 30,
  2004, the Company has paid a total of $75,000 under these agreements.

                               F-12
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 12 - COMMITMENTS AND CONTINGENCIES [Continued]

  Possible Claims Related to Previously Leased Mining Property - In August
  2001, Parent obtained 96.5% of the rights to certain mining claims in the
  Tintic Mining District of Juab County, Utah under the terms of a 5-year
  Mining Lease.  Under the terms of the lease, Parent was obligated to spend
  $15,000 over the term of the lease for exploration, mining, development or
  similar costs for the benefit of the property subject to the lease.  Parent
  was also obligated to pay a 3.5% net smelter royalty on all mineral-bearing
  ores sold.  The lease also gave a credit to Parent for the first $30,000 of
  net smelter royalties.  The lessor also agreed to indemnify and hold Parent
  harmless from any Environmental Protection Agency claim or claims by a
  similar state agency based solely on past mining contaminations or other
  environmental violations or damage.  In June 2003, Parent paid $3,459 to
  cancel the Mining Lease.  The Company's management believes that the
  Company would not be responsible for any future claims against the property
  which Parent previously leased, but the possibility exists that claims may
  arise against the property and the Company may be named in such claims
  based on the previous leasing arrangements.  The Company's management
  believes that the Company would be successful in defending against any such
  claims that may arise.  No accrual for possible losses or settlements has
  been recorded in the accompanying financial statements.

                               F-13
<PAGE>

ITEM 2 Management Discussion and Analysis or Plan of Operation

Plan of Reorganization.
-----------------------

          On June 24, 2003, a Share Purchase Agreement (the Agreement") was
executed by and between North Beck Joint Venture, LLC, a Utah limited
liability company ("North Beck"), that was the owner of approximately 96% of
the outstanding voting securities of the Registrant, as "Seller," and
LipidViro Tech, Inc., a privately-held Utah corporation ("LipidViro"), as
"Buyer."  Pursuant to the terms of the Agreement, LipidViro acquired 5,000,000
shares of the Registrant's common stock or approximately 96% of its
outstanding voting securities.  See the 8-K Current Report of the Registrant
dated June 24, 2003, which was previously filed with the Securities and
Exchange Commission on June 27, 2003, and which is incorporated herein by
reference.  See Item 7.

          The Registrant and LipidViro entered into an Agreement and Plan of
Reorganization (the "Reorganization Agreement"), a copy of which was attached
to the initial 8-K Current Report filed with the Securities and Exchange
Commission on September 9, 2003, and which is incorporated by reference, by
which LipidViro was to be acquired as a wholly-owned subsidiary of the
Registrant.  See Item 7.

          On August 19, 2003, LipidViro filed a Petition for Fairness Hearing
and a Motion for Expedited Hearing in the Third Judicial District Court in and
for Salt Lake County, State of Utah, respecting the Reorganization Agreement,
copies of which were also attached to the initial 8-K Current Report filed
with the Securities and Exchange Commission on September 9, 2003, and which
are also incorporated by reference.  The Petition for Fairness Hearing was
filed because of the 95% ownership of the Registrant by LipidViro and the fact
that following the closing of the Agreement with North Beck, the directors and
executive officers of LipidViro had been designated to serve as directors and
executive officers of the Registrant too.  See Item 7.

     The Fairness Hearing was requested in order for LipidViro's shareholders
to receive the contemplated issuance of securities under the Reorganization
Agreement in accordance with United States and Utah securities laws, and
pursuant to the exemption from registration provided in Section 3(a)(10) of
the Securities Act of 1933, as amended ("the Securities Act").  The Fairness
Hearing was held on September 8, 2003, and the Court took LipidViro's Petition
under advisement, after hearing oral argument, with the Court eventually
deferring to the Utah Division of Securities to conduct the Fairness Hearing,
based upon the recent adoption of an amendment to Section 61-1-11.1 of the
Utah Uniform Securities Act that granted the Utah Division of Securities
authority to conduct such hearings.  With (i) the Registrant being a Nevada
corporation, (ii) there being some question as to whether the Registrant or
LipidViro should petition for the Fairness Hearing and (iii) the Utah Division
of Securities having not formally adopted rules and regulations to implement
such hearings, the Registrant filed another Petition for Fairness Hearing in
the Fourth Judicial District Court of the State of Nevada, in and for the
County of Elko, for a Fairness Hearing on the Reorganization Agreement.

          The principal terms of the Reorganization Agreement were:

     1.   The LipidViro shareholders would deliver all of the LipidViro
securities held by LipidViro shareholders which shares and warrants shall
represented all of the issued and outstanding shares of LipidViro common stock
and "A" and "B" warrants, and the Registrant agreed to acquire such securities
in exchange for an aggregate of 9,818,750 shares of the Registrant's common
stock, par value $0.001 per share, for the LipidViro common stock, and
1,915,000 "A" warrants and 1,915,000 "B" like warrants of the Registrant for
the LipidViro warrants.

     2.   At the closing, the 5,000,000 shares of common stock of the
Registrant acquired by LipidViro from North Beck would be cancelled.

     3.   After giving effect to the Reorganization Agreement, the Registrant
would own all the issued and outstanding shares of LipidViro, and LipidViro
will be a wholly-owned subsidiary of the Registrant, operating under the name
"LipidViro Tech, Inc." or such other name selected by the shareholders and
management of LipidViro.

          On January 12, 2004, the Nevada Court conducted a Fairness Hearing
and found that the terms and provisions of the Reorganization Agreement and
the issuance and exchange of the securities of the Registrant and LipidViro
contemplated thereunder were fair to the Registrant's shareholders, based upon
the Registrant's acceptance of the terms of the Reorganization Agreement and
the information concerning the business and finances of the Registrant and
LipidViro, all of which was proffered to the Court by the Registrant's legal
counsel.

          Copies of this Petition for Fairness Hearing and the Court's Order
Granting Petition of Fairness were attached to the 8-KA Current Report dated
August 19, 2004, filed with the Securities and Exchange Commission on March
26, 2004, and are incorporated herein by reference.  See Item 7.

Plan of Operation.
------------------

     We are a development-stage biotechnology company, conducting research
focused on developing drug and biological products to treat infectious
pathogens and disease in which lipids or fat components play a key role.  We
have developed a technology based on a process that utilizes our lipid-
targeting investigational compound LVT3.  LVT3 is produced and delivered to
target pathogens by our proprietary drug production and delivery equipment. We
believe LVT3 and our proprietary process targets the lipids of certain
pathogens rendering them non-infectious.  Utilizing our proprietary process
and LVT3, we have commenced pre-clinical product development research designed
to:  (i) demonstrate the capacity of our technology to inactivate pathogens;
(ii) evaluate the toxicity and potential safety of our process; and (iii)
identify potential products for further development.

     Products we are currently evaluating for development include,
therapeutic treatments for diseases caused by infectious pathogens,
therapeutic treatments for lipid associated diseases and viral free
biologics.  We believe our unique lipid targeting technology has the potential
for inactivating or destroying a range of infectious and lipid rich pathogens,
including, the virus that cause SARS, West Nile, Asian Bird Flu, AIDS,
hepatitis B and C.  Many of the diseases caused by these viruses have
ineffective or poor treatment options.

     Our primary activities since incorporation have been developing drug
production and delivery equipment and conducting research to evaluate and
identify potential drug and biological products utilizing our proprietary
lipid targeting technology.  In addition, we have been performing business,
strategic and financial planning and raising capital.  We currently have no
approved, saleable products or services and we are accordingly, considered to
be a biotechnology company in the development stage.  During the first half of
2004, we funded operations and research from monies advanced from a
shareholder of the company.  We continue to seek long term financing to
support our research and operational activities.

Consultants
-----------

Whenever possible, we utilize unpaid consultants to perform certain functions
of our business, including (but not limited to): business development, product
development, strategic planning, corporate structuring, patent and
intellectual property strategies, research, drug development and, equipment
development.  No cash, stock or compensation of any kind has been paid or
promised to any unpaid consultant.

During the remainder of fiscal year 2004, we expect to utilize unpaid
consultants whenever possible to maintain low overhead expenses.  We also
anticipate using unpaid consultants, should they be available, during fiscal
year 2005.  In the event there are no unpaid consultants available to assists
us, we can manage all operational aspects of the Company without their
assistance.


Offices, Research Facilities
----------------------------

     We own no real estate and do not lease office space for management and
administrative functions.  All administrative functions are conducted from
home-based offices located in the homes of the officers and employees of the
company.  The Company has not had a need to rent office space and has no
anticipated need to lease office space for administrative and managerial
functions. The Company expects to continue the practice of conducting all
administrative and managerial functions from the home-based offices of
officers and employees of the Company, for the remainder of fiscal 2004 and
for fiscal year 2005.    There is no expense to the Company for these home
based offices, other than incidental offices supplies. At some point, we may
require additional office space requiring rental expense, but we do not
anticipate any such need during fiscal year 2004 or fiscal year 2005.

     We have outsourced our clinical research to independent laboratory
facilities in which our primary pre-clinical research is conducted.  These
laboratory facilities have available, and include equipment and laboratory
personnel necessary to conduct the Company's anticipated pre-clinical research
during fiscal year 2004.  In October 2003, the Company signed a one-year
agreement for the use of these research facilities, associated staff and a
research coordinator to conduct these activities.  The agreement obligates the
Company to pay up to $76,325 for supplies, facilities, a laboratory technician
and coordination efforts during fiscal year 2004; more if additional
disposable supplies are utilized during these research efforts.

     The Company has negotiated to extend this contract for an additional
year, with a larger research budget commensurate with the Company's
anticipated pre-clinical research program for fiscal year 2005.  The new
research agreement signed August 19, 2004 obligates the Company to pay up to
$600,000 for supplies, facilities, a laboratory technician and coordination
efforts during fiscal year 2005; The overall project design will be oriented
toward investigations that may lead to a potential in vitro, ex vivo or in
vivo process, drug or other therapeutic modality that resides within the
proprietary scope of LipidViro Tech's patented technology.


Pre-Clinical Laboratory Research, Product Development.
------------------------------------------------------

          Our pre-clinical, product development research is designed to
evaluate our proprietary technology and process. We utilize the results of our
pre-clinical research studies to identify potential products.  Each potential
product is ranked for development priority based on our assessment of the
product's prospects for commercial success. Our evaluation includes studying
the efficacy and toxicity of LVT3 in-vitro, the time, expense and anticipated
regulatory hurdles likely required to reach commercialization, and,
competition in that product category.

          Early research suggests our proprietary technology and process
possess a capacity to inactivate viruses and treat cardiovascular diseases.
While our research is preliminary and incomplete, and will require additional
research to verify, it does suggest the potential for multiple products that
we believe are worthy of further investigation.   Product categories we are
evaluating include: (i) processing biologicals for pathogen removal and
purification; (ii) developing therapeutics to treat serious infectious
diseases; (iii) developing therapeutics for treating lipid associated
diseases; and, (iv) developing treatments for cardiovascular diseases.

Overview - Equipment Development and Pre-Clinical Research.
-----------------------------------------------------------

         During the first fiscal quarter of 2004, we designed, engineered and
constructed the first generation of our proprietary drug manufacturing
equipment utilized in producing our investigational compound, LVT3.  We also
engineered and constructed the first ("GEN-1") and second generation ("GEN-2")
of our proprietary LVT3 drug delivery systems utilized in our Viral
Inactivation Platform.   After constructing and testing the equipment, we
commenced pre-clinical research of LVT3 with out GEN-2 technology.

     On March 29, 2004, we released pre-clinical research results of studies
that utilized LVT3 and our GEN-2 technology.  The results demonstrated
substantial inactivation of four different infectious viruses, including: a
DNA and a RNA virus, both with simple lipid envelopes; a DNA virus with a
complex lipid envelope; and, a small, non-enveloped virus.  The research was
sponsored by us and conducted by an independent laboratory. The studies were
performed in a variety of biological media chosen to represent potential
candidates for commercial products.  We are encouraged by these results, as a
demonstration of antiviral efficacy in four differently structured viruses
suggests a broad spectrum antiviral capacity, with the ability to inactivate
multiple families of viruses structured similarly to those studied.  See the
8-K Current Report dated and filed May 10, 2004, with the Securities and
Exchange Commission, which is incorporated herein by reference.  See Item 7.

     Also during the first quarter, we utilized results from hundreds of
studies performed with the GEN-1 and GEN-2 systems to further refine our drug
delivery technology, to maximize the efficacy of LVT3.  As a result of these
efforts, late in the first quarter, we completed engineering and construction
of our third generation ("GEN-3") drug delivery system.

     During the second fiscal quarter of 2004, we initiated performance
assessment of the newly constructed GEN-3 system, performed studies to further
evaluate our Viral Inactivation Platform, initiated a series of toxicity
studies and expanded the scope of our research by initiating prion research
and developing our Cardiovascular Platform.

     The viral inactivation studies were designed using infectious virus
prepared in artificially contaminated commercial bovine growth serum
preparations, and compared efficiency and performance to our earlier GEN-2
technology.  On May 10, 2004, we announced preliminary results of this
research.  The studies were conducted on an RNA-based, nucleo-enveloped
rhabdovirus, and demonstrated substantial inactivation of the measurable virus
in less than half the time required by the older GEN-2 technology.  In
addition, the studies demonstrated the new GEN-3 system required less than
half the dosage of LVT3 required by the earlier GEN-2 system to achieve
similar viral inactivation.  These improvements in the efficacy of delivering
LVT3 are very encouraging for our Viral Inactivation Platform, but also
translate directly to all of our disease Platforms, which will also utilize
the GEN-3 drug delivery technology.

Biological Fluid Purification.  During the third fiscal quarter 2004, we
designed studies to examine the effect of LVT3 delivered through our GEN-3
technology on a variety of biological fluids that we are considering for
potential commercial development.   These studies include the evaluation of
protein structure and cellular growth potential, both essential parameters in
the maintenance of the integrity of specific commercial products. These
studies are ongoing.

Prion Research.  During the second fiscal quarter of 2004, our contracted
laboratory facilities took part in and passed USDA and state health
inspections and applied for and received USDA licensing to purchase and
transport infectious prion material.   This allowed us to initate the
laboratory research required to investigate the ability of LVT3 to inactivate
prions.

During the third fiscal quarter of 2004 we designed and performed complex
studies which allowed us to identify the presence and quantify amounts of
infectious prion proteins in biological media.  The results of these studies
have allowed us to treat infectious prion proteins in artificially
contaminated biological media and determine if we could render it non-
infectious.  Based on the progress of these studies to date, we believe we
will obtain conclusive data to determine the ability of LVT3 and our
technology to inactivate prions during the fourth fiscal quarter, as
previously projected.

Cardiovascular Platform.  During the second fiscal quarter, we began
development and design of pre-clinical studies associated with our
Cardiovascular Platform. During the third fiscal quarter 2004, we engineered
and constructed the fourth generation of our proprietary drug delivery
technology, the "GEN-4H", designed specifically for use in human trials.  The
GEN-4H was designed specifically to develop pilot data from human studies
using our proprietary technology and our investigational compound LVT3.  These
data will allow us to evaluate LVT3 and our proprietary drug delivery
technology as a commercial therapeutic for the treatment of cardiovascular
diseases.

Late in the third fiscal quarter we initiated preliminary in-vitro studies
utilizing the new GEN-4H drug delivery system.  Theses early studies are
designed to evaluate biocompatibility, toxicity and performance for human use.
These studies are ongoing.

Intellectual Property.  We have filed for patent protection covering our LVT3
drug production and delivery technology and, and our GEN-1, GEN-2 GEN-3 and
GEN-4H drug delivery devices, and for proprietary applications utilized by our
process.

ITEM 3 CONTROLS AND PROCEDURES

     As of the end of the period covered by this Quarterly Report, we carried
out an evaluation, under the supervision and with the participation of our
President, of the effectiveness of our disclosure controls and procedures.
Based on this evaluation, our President concluded that our disclosure controls
and procedures are effective in timely alerting them to material information
required to be included in our periodic Securities and Exchange Commission
reports.  It should be noted that the design of any system of controls is
based in part upon certain assumptions about the likelihood of future events,
and there can be no assurance that any design will succeed in achieving its
stated goals under all potential future conditions, regardless of how remote.

In addition, we reviewed our internal controls over financial reporting, and
there have been no changes in our internal controls or in other factors in the
last fiscal quarter that has materially affected or is reasonably likely to
materially affect our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
          ------------------

          On November 10, 2004, the Third District Court of Salt Lake County,
Judge William Barrett presiding, granted Lipidviro's motion for summary
judgment on its primary claims against Natt Bottomley, Ross Bottomley, Jeff
Pace, and Advocates for Medizone. The court ruled that Lipidviro is entitled
to judgment in its favor on its claims for breach of contract, tortuous
interference with economic relations, and violations of the Utah Uniform Trade
Secrets Act.

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds.
          ------------------------------------------------------------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
          --------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
          ----------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
          ------------------

          None; not applicable

Item 6.   Exhibits and Reports on Form 8-K.
          ---------------------------------

          (a)  Exhibits.

          31 302 Certification of Kenneth P. Hamik

          32 906 Certification

          (b)  Reports on Form 8-K.

          8-K/A Report dated August 19, 2003, and filed March 26,
          2004,regarding Certificate of Amendment to the Articles
          Incorporation, Bylaws, Petition for Fairness Hearing, Agreement
          and Plan of Reorganization, Motion for Expedited Hearing, Petition
          for Fairness Hearing in the State of Nevada, Nevada Court
          Order Granting Petition of Fairness.

          8-K Current Report dated March 29, 2004, and filed March 30, 2004,
          regarding a press release.

          8-K Current Report dated and filed May 10, 2004, regarding a press
          release.

                               SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                     LIPIDVIRO TECH, INC.


Date: 11/11/2004                     By/s/Kenneth P. Hamik
      ----------                     -------------------
                                     Kenneth P. Hamik
                                     President, CFO and Director